BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20443773)

  • 1. IGF-I abuse in sport.
    Guha N; Dashwood A; Thomas NJ; Skingle AJ; Sönksen PH; Holt RI
    Curr Drug Abuse Rev; 2009 Sep; 2(3):263-72. PubMed ID: 20443773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone, IGF-I and insulin and their abuse in sport.
    Holt RI; Sönksen PH
    Br J Pharmacol; 2008 Jun; 154(3):542-56. PubMed ID: 18376417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Growth hormone and IGF-1 as doping agents in competitive sport].
    Jóźków P; Medraś M
    Endokrynol Pol; 2009; 60(5):389-94. PubMed ID: 19885810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF-I abuse in sport: current knowledge and future prospects for detection.
    Guha N; Sönksen PH; Holt RI
    Growth Horm IGF Res; 2009 Aug; 19(4):408-11. PubMed ID: 19467615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor I and insulin and their abuse in sport.
    Erotokritou-Mulligan I; Holt RI
    Endocrinol Metab Clin North Am; 2010 Mar; 39(1):33-43, viii. PubMed ID: 20122448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demographic factors influencing the GH system: Implications for the detection of GH doping in sport.
    Nelson AE; Ho KK
    Growth Horm IGF Res; 2009 Aug; 19(4):327-32. PubMed ID: 19481485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detection.
    Guha N; Cowan DA; Sönksen PH; Holt RI
    Anal Bioanal Chem; 2013 Dec; 405(30):9669-83. PubMed ID: 23934394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
    Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score.
    Erotokritou-Mulligan I; Eryl Bassett E; Cowan DA; Bartlett C; Milward P; Sartorio A; Sönksen PH; Holt RI
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):520-6. PubMed ID: 19650783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport.
    Guha N; Erotokritou-Mulligan I; Burford C; Strobridge G; Brigg J; Drake T; Bassett EE; Cowan D; Bartlett C; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2969-76. PubMed ID: 20410221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport.
    Wallace JD; Cuneo RC; Baxter R; Orskov H; Keay N; Pentecost C; Dall R; Rosén T; Jørgensen JO; Cittadini A; Longobardi S; Sacca L; Christiansen JS; Bengtsson BA; Sönksen PH
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3591-601. PubMed ID: 10523001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
    Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Values in selected population of athletes.
    Abellan R; Ventura R; Palmi I; di Carlo S; Bacosi A; Bellver M; Olive R; Pascual JA; Pacifici R; Segura J; Zuccaro P; Pichini S
    J Pharm Biomed Anal; 2008 Nov; 48(3):844-52. PubMed ID: 18617352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone induced increase in serum IGFBP-3 level is reversed by anabolic steroids in substance abusing power athletes.
    Karila T; Koistinen H; Seppälä M; Koistinen R; Seppälä T
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):459-63. PubMed ID: 9876343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-individual variation of GH-dependent markers in athletes: comparison of population based and individual thresholds for detection of GH abuse in sports.
    Kniess A; Ziegler E; Thieme D; Müller RK
    J Pharm Biomed Anal; 2013 Oct; 84():201-8. PubMed ID: 23850935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
    Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D
    Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detecting growth hormone abuse in athletes.
    Holt RI
    Drug Test Anal; 2009 Sep; 1(9-10):426-33. PubMed ID: 20355225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of hormones in doping and cancer risk.
    De Santi M; Baldelli G; Brandi G; ;
    Ann Ig; 2019; 31(6):590-594. PubMed ID: 31616903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum IGF-I and IGF binding proteins 2 and 3 as potential markers of doping with human GH.
    Kicman AT; Miell JP; Teale JD; Powrie J; Wood PJ; Laidler P; Milligan PJ; Cowan DA
    Clin Endocrinol (Oxf); 1997 Jul; 47(1):43-50. PubMed ID: 9302371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone in sport: beyond Beijing 2008.
    Segura J; Gutiérrez-Gallego R; Ventura R; Pascual JA; Bosch J; Such-Sanmartín G; Nikolovski Z; Pinyot A; Pichini S
    Ther Drug Monit; 2009 Feb; 31(1):3-13. PubMed ID: 19155963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.